[HTML][HTML] Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH2-terminal kinases

G Choukroun, R Hajjar, S Fry… - The Journal of …, 1999 - Am Soc Clin Investig
G Choukroun, R Hajjar, S Fry, F Del Monte, S Haq, JL Guerrero, M Picard, A Rosenzweig
The Journal of clinical investigation, 1999Am Soc Clin Investig
Cardiac hypertrophy often presages the development of heart failure. Numerous cytosolic
signaling pathways have been implicated in the hypertrophic response in cardiomyocytes in
culture, but their roles in the hypertrophic response to physiologically relevant stimuli in vivo
is unclear. We previously reported that adenovirus-mediated gene transfer of SEK-1 (KR), a
dominant inhibitory mutant of the immediate upstream activator of the stress-activated
protein kinases (SAPKs), abrogates the hypertrophic response of neonatal rat …
Cardiac hypertrophy often presages the development of heart failure. Numerous cytosolic signaling pathways have been implicated in the hypertrophic response in cardiomyocytes in culture, but their roles in the hypertrophic response to physiologically relevant stimuli in vivo is unclear. We previously reported that adenovirus-mediated gene transfer of SEK-1(KR), a dominant inhibitory mutant of the immediate upstream activator of the stress-activated protein kinases (SAPKs), abrogates the hypertrophic response of neonatal rat cardiomyocytes to endothelin-1 in culture. We now report that gene transfer of SEK-1(KR) to the adult rat heart blocks SAPK activation by pressure overload, demonstrating that the activity of cytosolic signaling pathways can be inhibited by gene transfer of loss-of-function mutants in vivo. Furthermore, gene transfer of SEK-1(KR) inhibited pressure overload–induced cardiac hypertrophy, as determined by echocardiography and several postmortem measures including left ventricular (LV) wall thickness, the ratio of LV weight to body weight, cardiomyocyte diameter, and inhibition of atrial natriuretic factor expression. Our data suggest that the SAPKs are critical regulators of cardiac hypertrophy in vivo, and therefore may serve as novel drug targets in the treatment of hypertrophy and heart failure.
J. Clin. Invest.104:391–398 (1999).
The Journal of Clinical Investigation